The JGOG 3016 showed that dose-dense paclitaxel and carboplatin (ddTC) improved progression-free survival (PFS) and overall survival (OS) in advanced ovarian cancer (AOC). ICON7 and GOG-0218 showed that bevacizumab (Bev) improved PFS. GOG-0262 suggested that ddTC+Bev showed no superiority in PFS. The aim of this study is to evaluate the efficacy and safety of ddTC+Bev compared with ddTC in AOC.
We retrospectively investigated patients with FIGO stage III-IV OC who received ddTC or ddTC+Bev as first-line chemotherapy. PFS was investigated about ddTC+Bev compared with ddTC using log-rank test. Age (<60 vs 60≤), FIGO stage (III vs IV), histological type (serous/endometrioid vs others), initial treatment (primary debulking surgery (PDS) vs neoadjuvant chemotherapy±interval debulking surgery (NAC±IDS)), debulking (complete vs others) and regimen (ddTC+Bev vs ddTC) were investigated by multivariate analysis using cox proportional hazards model to predict prognostic factors.
A total of 134 patients were enrolled. Median follow up periods was 30.5 months. 80.1% of patients had stage III disease. 76.7% had serous/endometrioid histologic findings. 59.7% received PDS. 61.9% received complete surgery.
Compared with ddTC, ddTC+Bev improved PFS (p<0.01). Multivariate analysis suggested that regimen, histological type, initial treatment, and debulking were independent variable. The frequency of adverse events grade 3/4 of -anemia (p=0.02), -hypertension (p=0.02) and -proteinuria (p<0.01) were higher in ddTC+Bev.
ddTC+Bev significantly prolonged PFS. Although the frequency of AE of ddTC+Bev is higher than ddTC, it is totally tolerable. ddTC+Bev is an effective 1st line regimen for AOC.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.